Supplemental Table 1: The protocol for the PET/MRI system for pre- and postoperative scans

	Protocol	Parameters	Voxel size (mm)	Slice-gap
3D	T1 MPRAGE	9° flip angle; TR/TE/TI 1900/2.52/900 ms	1x1x1	-
or Axial	T1-TIRM	150° flip angle; TR/TE/TI 2000/34/800 ms	0.45x0.45x4	1.2 mm
Axial + Coronal	T2-FLAIR (TIRM dark-fluid)	130° flip angle; TR/TE/TI 9000/95/2500 ms	0.43x0.43x4	0.4 mm
Axial	DWI (RESOLVE)	180° flip angle; TR/TE 5600/61 ms	1.15x1.15x4	1.2 mm
Intravenous contrast medium Gadovist 0.1 mmol/kg				
Axial	T2 BLADE	140° flip angle; TR/TE 4000/118 ms	0.72x0.72x5	1.5 mm
3D	T1 MPRAGE	9° flip angle; TR/TE/TI 1900/2.52/900 ms	1x1x1	-

MPRAGE: 3D-T1 magnetization prepared rapid gradient echo, TR: repetition time, TE: echo time TI: inversion time, DWI (diffusion weighted imaging): susceptibility-compensated, BLADE: with rotated parallel sampling to compensate motion.

Supplemental Table 2. STARD 2015 checklist.

Section & Topic	No	Item	Reported on page #
TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	2
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	2
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	3-4
	4	Study objectives and hypotheses	4
METHODS			
Study design	**5**	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	4-5
Participants	**6**	Eligibility criteria	4
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	4
	8	Where and when potentially eligible participants were identified (setting, location and dates)	4
	9	Whether participants formed a consecutive, random or convenience series	4
Test methods	**10a**	Index test, in sufficient detail to allow replication	6-7+table 1
	10b	Reference standard, in sufficient detail to allow replication	6-7
	11	Rationale for choosing the reference standard (if alternatives exist)	7
	12a	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	6
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	7
	13a	Whether clinical information and reference standard results were available to the performers/readers of the index test	6-7
	13b	Whether clinical information and index test results were available to the assessors of the reference standard	6-7
Analysis	**14**	Methods for estimating or comparing measures of diagnostic accuracy	7
	15	How indeterminate index test or reference standard results were handled	7
	16	How missing data on the index test and reference standard were handled	Table 1
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	No
	18	Intended sample size and how it was determined	No
RESULTS			
Participants	**19**	Flow of participants, using a diagram	4-5
	20	Baseline demographic and clinical characteristics of participants	4
	21a	Distribution of severity of disease in those with the target condition	Table 1
	21b	Distribution of alternative diagnoses in those without the target condition	No
	22	Time interval and any clinical interventions between index test and reference standard	Table 1
Test results	**23**	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	Table 1
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Table 2
	25	Any adverse events from performing the index test or the reference standard	No
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	11
	27	Implications for practice, including the intended use and clinical role of the index test	11
OTHER INFORMATION			
	28	Registration number and name of registry	NCT03402425
	29	Where the full study protocol can be accessed	NCT03402425

	30	Sources of funding and other support; role of funders	1